Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
901-920 of 1,738 trials

Colorectal Cancer: STC-1010 Immunotherapy

We are studying a new immunotherapy for patients with advanced colorectal cancer that cannot be surgically removed. The trial aims to evaluate its safety and effectiveness alongside standard treatment options.

Unresectable Locally Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Progressive Vitiligo: Anifrolumab and Phototherapy Study

We are investigating whether combining anifrolumab with phototherapy helps adults with progressive vitiligo regain skin color better than phototherapy alone. The study will also assess the safety and tolerability of this new treatment approach.

Vitiligo6-12 monthsEfficacy phase (II)Standard MedicinesAllergologyDermatology

Prostate Cancer: Re-treatment with [177Lu]Lu-PSMA

We are studying the effects of re-treating men with metastatic castration-resistant prostate cancer using [177Lu]Lu-PSMA. This trial aims to see if this treatment can help improve survival and quality of life.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncologyUrology

Head and Neck Cancer: Cetuximab with Chemotherapy

We are studying a combination of cetuximab and chemotherapy followed by immunotherapy for patients with recurrent or metastatic head and neck cancer. The goal is to see if this treatment improves survival and response rates for those with a specific PD-L1 score.

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Cancer Imaging: [18F]AlF-FAPI-74 PET/CT

We are studying a new imaging method for patients with newly diagnosed esophagogastric and pancreatic cancers. This trial aims to see if it detects cancer better than current imaging techniques.

Pancreatic CancerEsophagogastric AdenocarcinomaGastric Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Early Triple-Negative Breast Cancer: Durvalumab Study

We are investigating the effects of Durvalumab in patients with early-stage triple-negative breast cancer before surgery. This study aims to see if it can improve treatment outcomes.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Oncology

CNS Lymphoma: [90Y]Y-PentixaTher Therapy

We are studying the safety and effectiveness of [90Y]Y-PentixaTher in patients with recurrent or refractory central nervous system lymphoma. This trial aims to find the best dose and understand how the treatment works in the body.

CNS LymphomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Diffuse Large B-Cell Lymphoma: Selinexor Study

We are testing the drug Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma. This study aims to explore its potential effectiveness in treating this challenging condition.

Relapsed/Refractory Diffuse Large B-Cell LymphomaEfficacy phase (II)HematologyOncology

Colorectal Cancer: Encorafenib and Cetuximab with Pembrolizumab

We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Pancreatic Cancer: Digitoxin and Chemotherapy Study

We are exploring whether adding digitoxin to chemotherapy can help improve survival for patients with inoperable pancreatic cancer. The trial also looks at treatment safety and quality of life.

Pancreatic Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Prostate Cancer: Darolutamide Addition Study

We are studying whether adding darolutamide to standard treatment helps men with metastatic castration-resistant prostate cancer live longer without cancer progression.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Multiple Myeloma: Etentamig and Iberdomide Study

We are investigating the safety and effects of a new treatment combining etentamig and iberdomide for patients with relapsed or refractory multiple myeloma. This study aims to find the best doses and assess how well the treatment works.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

GLM101 for PMM2-CDG: Safety and Effects

We are studying the safety of GLM101 in patients with PMM2-CDG who have previously received the treatment. We will also look at its impact on coordination, balance, and sugar levels.

PMM2-CDGEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal Medicine

Cognitive and Motor Function Study: Donepezil in Older Adults

We are investigating whether a medication can improve thinking and movement tasks in elderly volunteers. This study compares the effects of donepezil to a placebo on brain activity and performance.

Neurological Disorders≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology

Burn Treatment in Children: New Skin Graft Study

We are testing a new skin graft made from the child's own cells for treating severe burns in children. The goal is to see if it works better and is safer than the standard skin graft method.

Children with Severe Burns1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatology

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Metastatic Melanoma: Early Detection of Side Effects

We are investigating whether a special imaging technique can help identify early side effects in patients receiving immune therapy for metastatic melanoma. This study aims to improve monitoring of immune-related side effects.

Malignant Melanoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ependymoma Treatment: SIOP Ependymoma II Program

We are exploring new chemotherapy options and surgical techniques for children and young adults with ependymoma. Our goal is to improve survival rates and treatment effectiveness compared to standard methods.

Ependymoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: Durvalumab Immunotherapy

We are studying whether durvalumab can help frail patients with limited small cell lung cancer live longer without disease progression after receiving thoracic chemoradiotherapy. The trial also examines the treatment's safety and its effects on quality of life.

Limited Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Takayasu Arteritis: Infliximab vs. Tocilizumab

We are studying whether Infliximab is more effective than Tocilizumab for patients with refractory or relapsing Takayasu arteritis. The goal is to see if it helps reduce disease activity and steroid use.

Takayasu's Arteritis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyRheumatology